Behavioral, Biological, and Chemical Perspectives on Targeting CRF(1) Receptor Antagonists to Treat Alcoholism

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2013 Jan 9

PMID 23294766

Citations 51

Authors

Eric P Zorrilla

Markus Heilig

Harriet de Wit

Yavin Shaham

Affiliations

Soon will be listed here.

Abstract

Background: Alcohol use disorders are chronic disabling conditions for which existing pharmacotherapies have only modest efficacy. In the present review, derived from the 2012 Behavior, Biology and Chemistry "Translational Research in Addiction" symposium, we summarize the anti-relapse potential of corticotropin-releasing factor type 1 (CRF(1)) receptor antagonists to reduce negative emotional symptoms of acute and protracted alcohol withdrawal and stress-induced relapse to alcohol seeking.

Methods: We review the biology of CRF(1) systems, the activity of CRF(1) receptor antagonists in animal models of anxiolytic and antidepressant activity, and experimental findings in alcohol addiction models. We also update the clinical trial status of CRF(1) receptor antagonists, including pexacerfont (BMS-562086), emicerfont (GW876008), verucerfont (GSK561679), CP316311, SSR125543A, R121919/NBI30775, R317573/19567470/CRA5626, and ONO-2333Ms. Finally, we discuss the potential heterogeneity and pharmacogenomics of CRF(1) receptor pharmacotherapy for alcohol dependence.

Results: The evidence suggests that brain penetrant-CRF(1) receptor antagonists have therapeutic potential for alcohol dependence. Lead compounds with clinically desirable pharmacokinetic properties now exist, and longer receptor residence rates (i.e., slow dissociation) may predict greater CRF(1) receptor antagonist efficacy. Functional variants in genes that encode CRF system molecules, including polymorphisms in Crhr1 (rs110402, rs1876831, rs242938) and Crhbp genes (rs10055255, rs3811939) may promote alcohol seeking and consumption by altering basal or stress-induced CRF system activation.

Conclusions: Ongoing clinical trials with pexacerfont and verucerfont in moderately to highly severe dependent anxious alcoholics may yield insight as to the role of CRF(1) receptor antagonists in a personalized medicine approach to treat drug or alcohol dependence.

Citing Articles

Stress-enhanced ethanol drinking does not increase sensitivity to the effects of a CRF-R1 antagonist on ethanol intake in male and female mice.

Nipper M, Helms M, Finn D, Ryabinin A Alcohol. 2024; 120:73-83.

PMID: 38185336 PMC: 11326135. DOI: 10.1016/j.alcohol.2024.01.001.

Chronic Alcohol Drinking Drives Sex-Specific Differences in Affective Behavior and Medial Prefrontal Cortex Activity in CRF1:Cre:tdTomato Transgenic Rats.

Quadir S, Arleth G, Cone M, High M, Ramage M, Effinger D eNeuro. 2023; 10(7).

PMID: 37414553 PMC: 10348447. DOI: 10.1523/ENEURO.0055-23.2023.

Synaptic Effects Induced by Alcohol.

Lovinger D, Roberto M Curr Top Behav Neurosci. 2023; .

PMID: 36765015 PMC: 11104446. DOI: 10.1007/7854_2022_412.

Corticotropin-Releasing Factor receptor 1 (CRF1) antagonism in patients with alcohol use disorder and high anxiety levels: effect on neural response during Trier Social Stress Test video feedback.

Lee M, Rio D, Kwako L, George D, Heilig M, Momenan R Neuropsychopharmacology. 2022; 48(5):816-820.

PMID: 36564531 PMC: 10066297. DOI: 10.1038/s41386-022-01521-z.

Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.

Fischler P, Soyka M, Seifritz E, Mutschler J Front Pharmacol. 2022; 13:927703.

PMID: 36263121 PMC: 9574013. DOI: 10.3389/fphar.2022.927703.

References

Le A, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y . The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl). 2000; 150(3):317-24. DOI: 10.1007/s002130000411. View

Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob G . Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci. 1995; 15(8):5439-47. PMC: 6577636. View

Vauquelin G, Fierens F, Van Liefde I . Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl. 2006; 24(1):S23-30. DOI: 10.1097/01.hjh.0000220403.61493.18. View

Habib K, Weld K, Rice K, Pushkas J, Champoux M, Listwak S . Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A. 2000; 97(11):6079-84. PMC: 18561. DOI: 10.1073/pnas.97.11.6079. View

Sanchez M, Young L, Plotsky P, Insel T . Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol. 1999; 408(3):365-77. View

Lacourciere Y, Asmar R . A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study..... Am J Hypertens. 2000; 12(12 Pt 1-2):1181-7. DOI: 10.1016/s0895-7061(99)00142-9. View

Nielsen D, Carey G, Gold L . Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol. 2004; 499(1-2):135-46. DOI: 10.1016/j.ejphar.2004.07.091. View

Vauquelin G, Van Liefde I . Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci. 2006; 27(7):356-9. DOI: 10.1016/j.tips.2006.05.001. View

Lelas S, Wong H, Li Y, Heman K, Ward K, Zeller K . Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1.... J Pharmacol Exp Ther. 2004; 309(1):293-302. DOI: 10.1124/jpet.103.058784. View

10.

Heinrichs S, de Souza E, Schulteis G, Lapsansky J, Grigoriadis D . Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 2002; 27(2):194-202. DOI: 10.1016/S0893-133X(02)00299-3. View

11.

Ramsey S, Attkins N, Fish R, van der Graaf P . Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Br J Pharmacol. 2011; 164(3):992-1007. PMC: 3195921. DOI: 10.1111/j.1476-5381.2011.01390.x. View

12.

Grigoriadis D, Liu X, Vaughn J, Palmer S, True C, Vale W . 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. Mol Pharmacol. 1996; 50(3):679-86. View

13.

Ciccocioppo R, Gehlert D, Ryabinin A, Kaur S, Cippitelli A, Thorsell A . Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol. 2009; 43(7):491-8. PMC: 2804869. DOI: 10.1016/j.alcohol.2009.08.003. View

14.

Liu X, Peprah D, Gershenfeld H . Tail-suspension induced hyperthermia: a new measure of stress reactivity. J Psychiatr Res. 2003; 37(3):249-59. DOI: 10.1016/s0022-3956(03)00004-9. View

15.

Chen Y, Mansbach R, Winter S, Brooks E, Collins J, Corman M . Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist. J Med Chem. 1997; 40(11):1749-54. DOI: 10.1021/jm960861b. View

16.

Kunzel H, Zobel A, Nickel T, Ackl N, Uhr M, Sonntag A . Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res. 2003; 37(6):525-33. DOI: 10.1016/s0022-3956(03)00070-0. View

17.

Le A, Shaham Y . Neurobiology of relapse to alcohol in rats. Pharmacol Ther. 2002; 94(1-2):137-56. DOI: 10.1016/s0163-7258(02)00200-0. View

18.

Zorrilla E, Koob G . The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs. 2004; 13(7):799-828. DOI: 10.1517/13543784.13.7.799. View

19.

Tummino P, Copeland R . Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry. 2008; 47(20):5481-92. DOI: 10.1021/bi8002023. View

20.

Overstreet D, Griebel G . Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol. 2004; 497(1):49-53. DOI: 10.1016/j.ejphar.2004.06.035. View